SCHEMBL30794657

SCHEMBL30794657

CCSc1nc(N2CCOCC2)cc(C)c1C(=O)NCc1cccc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BRAF P15056 17/20 0.48
HRH4 Q9H3N8 1/20 0.48
RAF1 P04049 16/20 0.48
TACR1 P25103 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2129102 1.00 BRAF (0.48) BRAFHRH4RAF1TACR1
SCHEMBL2131408 0.91 BRAF (0.47) BRAFRAF1TACR1
SCHEMBL30794720 0.91 BRAF (0.47) BRAFRAF1TACR1
SCHEMBL30795190 0.89 SRC (0.45)
SCHEMBL2130723 0.89 SRC (0.45)
SCHEMBL2130402 0.89 PIK3CB (0.47)
SCHEMBL30796012 0.89 PIK3CB (0.47)
SCHEMBL2129300 0.88 TACR1 (0.45) BRAFRAF1TACR1
SCHEMBL30796136 0.88 TACR1 (0.45) BRAFRAF1TACR1
SCHEMBL2130221 0.88 PIK3CB (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed